Core Viewpoint - COSCIENS Biopharma Inc. has appointed Anna Biehn as the new Chief Executive Officer, effective May 5, 2025, succeeding Gilles Gagnon, who will remain as a Strategic Advisor and Director [1][3]. Company Overview - COSCIENS Biopharma Inc. is a life science company that develops and commercializes a diversified portfolio of cosmeceutical, nutraceutical, and pharmaceutical products [5][6]. - The company focuses on leveraging proprietary extraction technology to produce active ingredients from renewable plant resources [5]. Leadership Transition - Anna Biehn brings over 25 years of experience in global general management and marketing, previously serving as Chief Financial Officer at NuTek Natural Ingredients [2][3]. - Gilles Gagnon has been with the company since 2008 and has played a key role in its growth and positioning [3]. Strategic Vision - The company aims to establish itself as a global leader in natural-based products for health and wellness, capitalizing on the growing demand for natural ingredients [3][4]. - Biehn expressed confidence in COSCIENS' portfolio and technology, highlighting significant innovation opportunities for both near-term and long-term value [3]. Market Position - COSCIENS is listed on both the Nasdaq Capital Market and the Toronto Stock Exchange under the ticker symbol "CSCI" [6].

Core Insights - Mangoceuticals, Inc. has secured exclusive licensing and distribution rights for Diabetinol® in the U.S. and Canada, targeting the pre-diabetic and weight loss markets [1][3] - Diabetinol® is a patented plant-based nutraceutical derived from citrus peel, clinically shown to improve insulin sensitivity and metabolic health [2][6] - The product aims to address the growing diabetes crisis, with over 30 million Americans suffering from type 2 diabetes and 97.6 million adults having prediabetes [4][5] Market Opportunity - The addressable market for diabetes and metabolic health solutions is valued at $33.66 billion [3] - U.S. diabetes-related healthcare costs exceed $400 billion annually, while global spending on weight loss and blood sugar-lowering medications is projected to surpass $131 billion by 2028 [5] - There is a significant demand for affordable metabolic health solutions, as many individuals discontinue second-line therapies due to cost or tolerability [5][6] Product Details - Diabetinol® will be available in various consumer-friendly formats, including capsules, beverages, pouches, cookies, and gummies [7] - The product is designed to deliver consistent clinical levels of active ingredients and will be marketed through direct-to-consumer online initiatives and retail outlets [7] Clinical Support - Clinical studies indicate that Diabetinol® can significantly improve health markers in patients with type 2 diabetes or prediabetes, including reductions in Hemoglobin A1c and improvements in cholesterol and blood pressure levels [12] - In a pilot study, Diabetinol® reduced peak postprandial blood glucose by approximately 50 mg/dL, which is clinically meaningful for managing glucose metabolism [11] Strategic Vision - The introduction of Diabetinol® aligns with the company's mission to provide safe and accessible wellness solutions amid a growing public demand for natural health products [10] - The product reflects a shift towards preventive, plant-based solutions in healthcare, as emphasized by health leaders [10]

Financial Data and Key Metrics Changes - In Q4 2024, the company reported record revenues of $29.1 million, a 37% increase year-over-year, and net income of $7.2 million [8][23] - For the full year 2024, net revenues reached $99.6 million, reflecting a 19% growth year-over-year, with net income of $8.6 million, a significant turnaround from a net loss of $4.9 million in 2023 [8][22] - The company generated $12.1 million in positive cash flow from operations in 2024, ending the year with $44.7 million in cash and no debt [9][28] Business Line Data and Key Metrics Changes - E-commerce channel net sales were $17.3 million, a 30% increase year-over-year, while food-grade and pharmaceutical-grade Niagen ingredient sales reached $5.3 million, a 96% increase year-over-year [9][24] - Tru Niagen-related sales increased by 29%, driven by a 30% growth in e-commerce and a 26% increase in combined Watsons and other B2B sales [23][24] Market Data and Key Metrics Changes - The company noted a growing demand for NAD-boosting products, with an increase in companies entering the market, some of which engage in misleading practices [10][11] - The company is actively working to address fraudulent activities in the market and is advocating for more regulatory oversight [11][105] Company Strategy and Development Direction - The company plans to leverage its position as an industry leader to promote consumer safety and product excellence [12] - A name change is anticipated to better align with the company's evolving mission and strategic direction [16][33] - The company is focused on expanding its pharmaceutical-grade ingredient business and enhancing its e-commerce presence [30][32] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, highlighting the company's strong financial discipline and operational efficiency [22][32] - The company expects approximately 18% growth in net sales for 2025, driven by e-commerce expansion and established partnerships [30][32] - Management acknowledged potential risks related to supply chain issues but indicated confidence in resolving these challenges [62] Other Important Information - The company has initiated communication with the FDA regarding an investigational new drug application for NR in treating ataxia telangiectasia and is awaiting results from the NO-PARK study for Parkinson's disease [15][16] - The company plans to introduce new formulations and enhance existing products, including a subcutaneous injection version of Niagen [84] Q&A Session Summary Question: Can you discuss the stick packs and their performance? - The stick packs contain 300 milligrams and have seen increased sales, with plans for a marketing campaign in 2025 [36] Question: What is the status of the Elysium settlement? - The second payment of $1.3 million from the Elysium settlement is expected by the end of March [40] Question: When can we expect results from the NO-PARK study? - The study will be completed by June, but results may not be available until later [42] Question: How is the food-grade Niagen segment performing? - The food-grade ingredient business is expected to continue growing, with increased awareness and new partnerships [45] Question: What are the drivers behind strong e-commerce performance? - Improvements in Shopify performance and increased awareness of NAD contributed to e-commerce growth [54] Question: What is the company's strategy regarding supply chain risks? - The company has resolved previous supply chain issues and expects to maintain a steady supply moving forward [62] Question: What are the potential market opportunities for the Parkinson's study? - A positive outcome could significantly increase demand, with a large addressable market for those diagnosed with Parkinson's disease [112] Question: Will there be a spin-off for pharmaceutical initiatives? - A spin-off is a possibility if capital is insufficient for drug approval, but it is not currently expected [118]

As filed with the Securities and Exchange Commission on February 14, 2025. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 6 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FUNCTIONAL BRANDS INC. (formerly HT Naturals Inc.) (Exact name of registrant as specified in its charter) Delaware 325411 85-4094332 (I.R.S. Employer (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Identificat ...

As filed with the Securities and Exchange Commission on January 8, 2025. Registration No. 333-[●] UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 325411 85-4094332 FORM S-1 (I.R.S. Employer Identification Number) 6400 SW Rosewood Street Lake Oswego, Oregon 97035 REGISTRATION STATEMENT UNDER THE SECURITI ...